A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
Public ClinicalTrials.gov record NCT02782104. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label Long-term Extension Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety and tolerability of esketamine nasal spray in participants with treatment-resistant depression (TRD).
Study identification
- NCT ID
- NCT02782104
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,148 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 8, 2016
- Primary completion
- Dec 29, 2022
- Completion
- Dec 29, 2022
- Last update posted
- Apr 28, 2025
2016 – 2022
United States locations
- U.S. sites
- 51
- U.S. states
- 25
- U.S. cities
- 51
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Garden Grove | California | — | — |
| Not listed | Glendale | California | — | — |
| Not listed | Oakland | California | — | — |
| Not listed | Orange | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | San Rafael | California | — | — |
| Not listed | Hartford | Connecticut | — | — |
| Not listed | New Haven | Connecticut | — | — |
| Not listed | Gainesville | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Hoffman Estates | Illinois | — | — |
| Not listed | Joliet | Illinois | — | — |
| Not listed | Maywood | Illinois | — | — |
| Not listed | Skokie | Illinois | — | — |
| Not listed | Iowa City | Iowa | — | — |
| Not listed | Wichita | Kansas | — | — |
| Not listed | Lake Charles | Louisiana | — | — |
| Not listed | Shreveport | Louisiana | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Gaithersburg | Maryland | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | New Bedford | Massachusetts | — | — |
| Not listed | Watertown | Massachusetts | — | — |
| Not listed | Worcester | Massachusetts | — | — |
| Not listed | Rochester Hills | Michigan | — | — |
| Not listed | O'Fallon | Missouri | — | — |
| Not listed | Saint Charles | Missouri | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Cedarhurst | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Staten Island | New York | — | — |
| Not listed | Hickory | North Carolina | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Allentown | Pennsylvania | — | — |
| Not listed | Media | Pennsylvania | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Lincoln | Rhode Island | — | — |
| Not listed | Providence | Rhode Island | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Wichita Falls | Texas | — | — |
| Not listed | Charlottesville | Virginia | — | — |
| Not listed | Waukesha | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 122 non-U.S. sites.
Recently updated Depressive Disorder, Treatment-Resistant trials
Other public records listing Depressive Disorder, Treatment-Resistant. Sorted by last update posted; newest first. Not a recommendation.
- NCT07758010: One-Day cTBS Over the Precuneus Not yet recruiting
- NCT07716098: A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression Recruiting
- NCT07284667: ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response Recruiting
- NCT02994433: NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits Recruiting
- NCT03851380: Improving Brain Stimulation Through Imaging Active, not recruiting
- NCT06511908: Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02782104, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 28, 2025 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02782104 live on ClinicalTrials.gov.